Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,6783121,half-life,The inhibitor is excreted with a half-life of about 7 h; it is not metabolized.,Distribution of conduritol B epoxide in the animal model for Gaucher's disease (Gaucher mouse). ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6783121/),h,7,3180,DB03106,Myo-Inositol
,27121673,trough concentration,"During the apparent steady state, ELND005 plasma levels rapidly peaked at 39.8 µg/mL and decreased to an average trough concentration of 10.6 µg/mL at the end of the 12-hour dosing regimen.","Pharmacokinetic Profile of Orally Administered Scyllo-Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid-Beta in Healthy Subjects. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121673/),[μg] / [ml],10.6,3572,DB03106,Myo-Inositol
,27121673,trough concentrations,"In contrast, CSF drug levels slowly peaked at 13.7 µg/mL and remained near the same level with average trough concentrations of 12.4 µg/mL.","Pharmacokinetic Profile of Orally Administered Scyllo-Inositol (Elnd005) in Plasma, Cerebrospinal Fluid and Brain, and Corresponding Effect on Amyloid-Beta in Healthy Subjects. ",Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27121673/),[μg] / [ml],12.4,3573,DB03106,Myo-Inositol
,16223868,affinities,All five analogs bound to guinea pig progesterone binding globulin with relatively high affinities (264-1020 nM).,Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16223868/),nM,264-1020,4000,DB03106,Myo-Inositol
,16223868,binding affinity,Conjugation via the epsilon-amino function of D-Lys6 (conjugates A and B) produced compounds with high binding affinity for the human GnRH receptor (15 and 7 nM) comparable to that of the unconjugated GnRH antagonists (4 and 26 nM).,Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16223868/),nM,15,4001,DB03106,Myo-Inositol
,16223868,binding affinity,Conjugation via the epsilon-amino function of D-Lys6 (conjugates A and B) produced compounds with high binding affinity for the human GnRH receptor (15 and 7 nM) comparable to that of the unconjugated GnRH antagonists (4 and 26 nM).,Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16223868/),nM,7,4002,DB03106,Myo-Inositol
,16223868,binding affinity,Conjugation via the epsilon-amino function of D-Lys6 (conjugates A and B) produced compounds with high binding affinity for the human GnRH receptor (15 and 7 nM) comparable to that of the unconjugated GnRH antagonists (4 and 26 nM).,Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16223868/),nM,4,4003,DB03106,Myo-Inositol
,16223868,binding affinity,Conjugation via the epsilon-amino function of D-Lys6 (conjugates A and B) produced compounds with high binding affinity for the human GnRH receptor (15 and 7 nM) comparable to that of the unconjugated GnRH antagonists (4 and 26 nM).,Bifunctional gonadotropin-releasing hormone antagonist-progesterone analogs with increased efficacy and duration of action. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16223868/),nM,26,4004,DB03106,Myo-Inositol
,25808120,Cmax,"Trp-His was absorbed intact into SD rat blood, showing a maximal level at 1 h after administration at 10 mg/kg dose (Cmax , 28.7 ± 8.9 pmol/mL-plasma; area under the curve, 71.3 ± 18.7 pmol·h/mL-plasma).","Visualized absorption of anti-atherosclerotic dipeptide, Trp-His, in Sprague-Dawley rats by LC-MS and MALDI-MS imaging analyses. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25808120/),[pM] / [ml-plasma],28.7,16615,DB03106,Myo-Inositol
,25808120,area under the curve,"Trp-His was absorbed intact into SD rat blood, showing a maximal level at 1 h after administration at 10 mg/kg dose (Cmax , 28.7 ± 8.9 pmol/mL-plasma; area under the curve, 71.3 ± 18.7 pmol·h/mL-plasma).","Visualized absorption of anti-atherosclerotic dipeptide, Trp-His, in Sprague-Dawley rats by LC-MS and MALDI-MS imaging analyses. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25808120/),[h·pM] / [ml-plasma],71.3,16616,DB03106,Myo-Inositol
,23782587,maximum inhibition,The percentage of DPP-4 inhibition by vildagliptin remained unchanged when vildagliptin was given alone or co-administered with voglibose; maximum inhibition was 98.3 ± 1.4% (mean ± SD) for vildagliptin alone and 97.4 ± 1.1% with co-administration.,Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782587/),%,98.3,17286,DB03106,Myo-Inositol
,23782587,maximum inhibition,The percentage of DPP-4 inhibition by vildagliptin remained unchanged when vildagliptin was given alone or co-administered with voglibose; maximum inhibition was 98.3 ± 1.4% (mean ± SD) for vildagliptin alone and 97.4 ± 1.1% with co-administration.,Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782587/),%,97.4,17287,DB03106,Myo-Inositol
,9816216,t(1/2)alpha,Quercetin pharmacokinetics were described by a first-order two-compartment model with a median t(1/2)alpha of 6 min and median t(1/2)beta of 43 min.,Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816216/),min,6,20404,DB03106,Myo-Inositol
,9816216,t(1/2)beta,Quercetin pharmacokinetics were described by a first-order two-compartment model with a median t(1/2)alpha of 6 min and median t(1/2)beta of 43 min.,Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816216/),min,43,20405,DB03106,Myo-Inositol
,9816216,clearance,"The median estimated clearance was 0.28 liter/min/m2, and median volume of distribution at steady state was 3.7 liter/m2.",Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816216/),[l] / [m2·min],0.28,20406,DB03106,Myo-Inositol
,9816216,volume of distribution at steady state,"The median estimated clearance was 0.28 liter/min/m2, and median volume of distribution at steady state was 3.7 liter/m2.",Phase I clinical trial of the flavonoid quercetin: pharmacokinetics and evidence for in vivo tyrosine kinase inhibition. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9816216/),[l] / [m2],3.7,20407,DB03106,Myo-Inositol
,9804702,IC50,"Further structure-activity studies have now established that for high NK1 affinity the benzyl ether side chain must be 3,5-disubstituted and highly lipophilic, the optimal side chain being the 3, 5-bis(trifluoromethyl)benzyl ether, 12 (hNK1 IC50 = 0.95 nM).","4,4-Disubstituted piperidine high-affinity NK1 antagonists: structure-activity relationships and in vivo activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9804702/),nM,0.95,28719,DB03106,Myo-Inositol
,9804702,IC50,"Additional studies have shown that this class of NK1 antagonist tolerates a wider range of substituents on the piperidine nitrogen, including acyl (38) (hNK1 IC50 = 5.3 nM) and sulfonyl (39) (hNK1 IC50 = 5.7 nM) derivatives.","4,4-Disubstituted piperidine high-affinity NK1 antagonists: structure-activity relationships and in vivo activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9804702/),nM,5.3,28720,DB03106,Myo-Inositol
,9804702,IC50,"Additional studies have shown that this class of NK1 antagonist tolerates a wider range of substituents on the piperidine nitrogen, including acyl (38) (hNK1 IC50 = 5.3 nM) and sulfonyl (39) (hNK1 IC50 = 5.7 nM) derivatives.","4,4-Disubstituted piperidine high-affinity NK1 antagonists: structure-activity relationships and in vivo activity. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9804702/),nM,5.7,28721,DB03106,Myo-Inositol
,9804702,ID50,"Following preliminary pharmacokinetic analysis, two compounds (32 and 43) were selected for in vivo study in the resiniferotoxin-induced vascular leakage model, both showing excellent profiles (ID50 = 0.22 and 0.28 mg/kg, respectively).","4,4-Disubstituted piperidine high-affinity NK1 antagonists: structure-activity relationships and in vivo activity. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9804702/),[mg] / [kg],0.22,28722,DB03106,Myo-Inositol
,9804702,ID50,"Following preliminary pharmacokinetic analysis, two compounds (32 and 43) were selected for in vivo study in the resiniferotoxin-induced vascular leakage model, both showing excellent profiles (ID50 = 0.22 and 0.28 mg/kg, respectively).","4,4-Disubstituted piperidine high-affinity NK1 antagonists: structure-activity relationships and in vivo activity. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9804702/),[mg] / [kg],0.28,28723,DB03106,Myo-Inositol
,15637285,IC(50),"It possesses potent antagonist activity at the human CaR with IC(50) values of 64 nm and 230 nm in inhibiting intracellular Ca(2+) flux and inositol phosphate generation in vitro, respectively.",A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15637285/),nm,64,39561,DB03106,Myo-Inositol
,15637285,IC(50),"It possesses potent antagonist activity at the human CaR with IC(50) values of 64 nm and 230 nm in inhibiting intracellular Ca(2+) flux and inositol phosphate generation in vitro, respectively.",A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo. ,IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15637285/),nm,230,39562,DB03106,Myo-Inositol
,15637285,half-life,The pharmacokinetic profile of compound 1 after oral administration revealed that maximal plasma levels of compound were reached within 1 h and the half-life of the compound to be approximately 2 h in rats.,A novel calcium-sensing receptor antagonist transiently stimulates parathyroid hormone secretion in vivo. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15637285/),h,2,39563,DB03106,Myo-Inositol
,19879867,pK(i),"Both compounds demonstrated high affinity for recombinant human (pK(i) values 7.7 and 8.9, respectively) and native guinea pig (pK(i) values 7.8 and 8.4, respectively) tachykinin NK(3) receptors.",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),,7.7,63805,DB03106,Myo-Inositol
,19879867,pK(i),"Both compounds demonstrated high affinity for recombinant human (pK(i) values 7.7 and 8.9, respectively) and native guinea pig (pK(i) values 7.8 and 8.4, respectively) tachykinin NK(3) receptors.",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),,8.9,63806,DB03106,Myo-Inositol
,19879867,pK(i),"Both compounds demonstrated high affinity for recombinant human (pK(i) values 7.7 and 8.9, respectively) and native guinea pig (pK(i) values 7.8 and 8.4, respectively) tachykinin NK(3) receptors.",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),,7.8,63807,DB03106,Myo-Inositol
,19879867,pK(i),"Both compounds demonstrated high affinity for recombinant human (pK(i) values 7.7 and 8.9, respectively) and native guinea pig (pK(i) values 7.8 and 8.4, respectively) tachykinin NK(3) receptors.",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),,8.4,63808,DB03106,Myo-Inositol
,19879867,pA(2),"In vitro functional evaluations revealed GSK172981 to be a competitive antagonist (pA(2)=7.2) at cloned human tachykinin NK(3) receptor whereas GSK256471 diminished the neurokinin B-induced E(max) response, indicative of non-surmountable antagonist pharmacology (pA(2)=9.2).",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),,7.2,63809,DB03106,Myo-Inositol
,19879867,pA(2),"In vitro functional evaluations revealed GSK172981 to be a competitive antagonist (pA(2)=7.2) at cloned human tachykinin NK(3) receptor whereas GSK256471 diminished the neurokinin B-induced E(max) response, indicative of non-surmountable antagonist pharmacology (pA(2)=9.2).",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),,9.2,63810,DB03106,Myo-Inositol
,19879867,apparent pK(B),"GSK172981 also exhibited a competitive profile in antagonizing neurokinin B-stimulated neuronal activity recorded from the guinea pig medial habenula slices (apparent pK(B)=8.1), whilst GSK256471 abolished the agonist-induced response.",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),,8.1,63811,DB03106,Myo-Inositol
,19879867,ED(50),"Central nervous system penetration by GSK172981 and GSK256471 was indicated by dose-dependent ex vivo tachykinin NK(3) receptor occupancy in medial prefrontal cortex (ED(50) values of 0.8 and 0.9 mg/kg, i.p., respectively) and the dose-dependent attenuation of agonist-induced ""wet dog shake"" behaviours in guinea pigs.",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),[mg] / [kg],0.8,63812,DB03106,Myo-Inositol
,19879867,ED(50),"Central nervous system penetration by GSK172981 and GSK256471 was indicated by dose-dependent ex vivo tachykinin NK(3) receptor occupancy in medial prefrontal cortex (ED(50) values of 0.8 and 0.9 mg/kg, i.p., respectively) and the dose-dependent attenuation of agonist-induced ""wet dog shake"" behaviours in guinea pigs.",In vitro and in vivo comparison of two non-peptide tachykinin NK3 receptor antagonists: Improvements in efficacy achieved through enhanced brain penetration or altered pharmacological characteristics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19879867/),[mg] / [kg],0.9,63813,DB03106,Myo-Inositol
,23347001,disappearance,"The mean IHN disappearance and NA appearance half-lives were 1.07 and 3.93 h in human plasma, and 0.152 and 2.68 h in rat plasma.",Biotransformation and pharmacokinetics of inositol hexanicotinate in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23347001/),h,1.07,64098,DB03106,Myo-Inositol
,23347001,disappearance,"The mean IHN disappearance and NA appearance half-lives were 1.07 and 3.93 h in human plasma, and 0.152 and 2.68 h in rat plasma.",Biotransformation and pharmacokinetics of inositol hexanicotinate in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23347001/),h,0.152,64099,DB03106,Myo-Inositol
,23347001,appearance half-lives,"The mean IHN disappearance and NA appearance half-lives were 1.07 and 3.93 h in human plasma, and 0.152 and 2.68 h in rat plasma.",Biotransformation and pharmacokinetics of inositol hexanicotinate in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23347001/),h,3.93,64100,DB03106,Myo-Inositol
,23347001,appearance half-lives,"The mean IHN disappearance and NA appearance half-lives were 1.07 and 3.93 h in human plasma, and 0.152 and 2.68 h in rat plasma.",Biotransformation and pharmacokinetics of inositol hexanicotinate in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23347001/),h,0.152,64101,DB03106,Myo-Inositol
,23347001,appearance half-lives,"The mean IHN disappearance and NA appearance half-lives were 1.07 and 3.93 h in human plasma, and 0.152 and 2.68 h in rat plasma.",Biotransformation and pharmacokinetics of inositol hexanicotinate in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23347001/),h,2.68,64102,DB03106,Myo-Inositol
,23347001,appearance half-life,"Increasing the initial plasma concentration to 50 µg/mL increased the NA appearance half-life in human and rat plasma to 4.66 and 6.47 h, respectively.",Biotransformation and pharmacokinetics of inositol hexanicotinate in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23347001/),h,4.66,64103,DB03106,Myo-Inositol
,23347001,appearance half-life,"Increasing the initial plasma concentration to 50 µg/mL increased the NA appearance half-life in human and rat plasma to 4.66 and 6.47 h, respectively.",Biotransformation and pharmacokinetics of inositol hexanicotinate in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23347001/),h,6.47,64104,DB03106,Myo-Inositol
,25040039,Cmax,"Pharmacokinetic data showed AQX-1125 was rapidly absorbed with geometric mean Cmax and AUC0-24 h values of 1417 ng/mL and 16 727 h ng/mL, respectively.",The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25040039/),[ng] / [ml],1417,69032,DB03106,Myo-Inositol
,25040039,AUC0-24 h,"Pharmacokinetic data showed AQX-1125 was rapidly absorbed with geometric mean Cmax and AUC0-24 h values of 1417 ng/mL and 16 727 h ng/mL, respectively.",The effects of the novel SHIP1 activator AQX-1125 on allergen-induced responses in mild-to-moderate asthma. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25040039/),[h·ng] / [ml],16 727,69033,DB03106,Myo-Inositol
,21985634,IC(50),Empagliflozin has an IC(50) of 3.1 nM for hSGLT-2.,"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985634/),nM,3.1,70622,DB03106,Myo-Inositol
,21985634,half-life,Its binding to SGLT-2 is competitive with glucose (half-life approximately 1 h).,"Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21985634/),h,1,70623,DB03106,Myo-Inositol
,16177199,Fractional Ca absorption,"Fractional Ca absorption in CCSM (0.211 +/- 0.057) did not differ from that of cow's milk (0.217 +/- 0.040), but both were higher (P < 0.05) than that of TCPSM (0.181 +/- 0.039).",Calcium bioavailability of calcium carbonate fortified soymilk is equivalent to cow's milk in young women. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16177199/),,0.211,72399,DB03106,Myo-Inositol
,16177199,Fractional Ca absorption,"Fractional Ca absorption in CCSM (0.211 +/- 0.057) did not differ from that of cow's milk (0.217 +/- 0.040), but both were higher (P < 0.05) than that of TCPSM (0.181 +/- 0.039).",Calcium bioavailability of calcium carbonate fortified soymilk is equivalent to cow's milk in young women. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16177199/),,0.217,72400,DB03106,Myo-Inositol
,16177199,Fractional Ca absorption,"Fractional Ca absorption in CCSM (0.211 +/- 0.057) did not differ from that of cow's milk (0.217 +/- 0.040), but both were higher (P < 0.05) than that of TCPSM (0.181 +/- 0.039).",Calcium bioavailability of calcium carbonate fortified soymilk is equivalent to cow's milk in young women. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16177199/),,0.181,72401,DB03106,Myo-Inositol
,21849627,brain/plasma ratio,CTEP penetrates the brain with a brain/plasma ratio of 2.6 and displaces the tracer [(3)H]3-(6-methyl-pyridin-2-ylethynyl)-cyclohex-2-enone-O-methyl-oxime (ABP688) in vivo in mice from brain regions expressing mGlu5 with an average ED(50) equivalent to a drug concentration of 77.5 ng/g in brain tissue.,"CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21849627/),,2.6,89632,DB03106,Myo-Inositol
,21849627,minimal effective doses,"This novel mGlu5 inhibitor is active in the stress-induced hyperthermia procedure in mice and the Vogel conflict drinking test in rats with minimal effective doses of 0.1 and 0.3 mg/kg, respectively, reflecting a 30- to 100-fold higher in vivo potency compared with 2-methyl-6-(phenylethynyl)pyridine (MPEP) and fenobam.","CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21849627/),[mg] / [kg],0.1,89633,DB03106,Myo-Inositol
,21849627,minimal effective doses,"This novel mGlu5 inhibitor is active in the stress-induced hyperthermia procedure in mice and the Vogel conflict drinking test in rats with minimal effective doses of 0.1 and 0.3 mg/kg, respectively, reflecting a 30- to 100-fold higher in vivo potency compared with 2-methyl-6-(phenylethynyl)pyridine (MPEP) and fenobam.","CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21849627/),[mg] / [kg],0.3,89634,DB03106,Myo-Inositol
,21849627,half-life,CTEP is the first reported mGlu5 inhibitor with both long half-life of approximately 18 h and high oral bioavailability allowing chronic treatment with continuous receptor blockade with one dose every 48 h in adult and newborn animals.,"CTEP: a novel, potent, long-acting, and orally bioavailable metabotropic glutamate receptor 5 inhibitor. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21849627/),h,18,89635,DB03106,Myo-Inositol
,26504409,peak serum concentration (C Max),"Day 1 PK parameters (adjusted for body weight) for arginine were peak serum concentration (C Max) 30.06±7.80 μg/mL, time it takes to reach peak serum concentration (t Max) 1.13±0.52 hours, and time required to reach half its original concentration (t 1/2) 15.93±9.55 hours and for silicon were C Max 2.99±0.63 μg/mL, t Max 2.44±2.05 hours, and t 1/2 34.56±16.56 hours.","A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26504409/),[μg] / [ml],30.06,95769,DB03106,Myo-Inositol
,26504409,time it takes to reach peak serum concentration (t Max),"Day 1 PK parameters (adjusted for body weight) for arginine were peak serum concentration (C Max) 30.06±7.80 μg/mL, time it takes to reach peak serum concentration (t Max) 1.13±0.52 hours, and time required to reach half its original concentration (t 1/2) 15.93±9.55 hours and for silicon were C Max 2.99±0.63 μg/mL, t Max 2.44±2.05 hours, and t 1/2 34.56±16.56 hours.","A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26504409/),h,1.13,95770,DB03106,Myo-Inositol
,26504409,C Max,"Day 1 PK parameters (adjusted for body weight) for arginine were peak serum concentration (C Max) 30.06±7.80 μg/mL, time it takes to reach peak serum concentration (t Max) 1.13±0.52 hours, and time required to reach half its original concentration (t 1/2) 15.93±9.55 hours and for silicon were C Max 2.99±0.63 μg/mL, t Max 2.44±2.05 hours, and t 1/2 34.56±16.56 hours.","A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26504409/),[μg] / [ml],2.99,95771,DB03106,Myo-Inositol
,26504409,t Max,"Day 1 PK parameters (adjusted for body weight) for arginine were peak serum concentration (C Max) 30.06±7.80 μg/mL, time it takes to reach peak serum concentration (t Max) 1.13±0.52 hours, and time required to reach half its original concentration (t 1/2) 15.93±9.55 hours and for silicon were C Max 2.99±0.63 μg/mL, t Max 2.44±2.05 hours, and t 1/2 34.56±16.56 hours.","A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26504409/),h,2.44,95772,DB03106,Myo-Inositol
,26504409,t 1/2,"Day 1 PK parameters (adjusted for body weight) for arginine were peak serum concentration (C Max) 30.06±7.80 μg/mL, time it takes to reach peak serum concentration (t Max) 1.13±0.52 hours, and time required to reach half its original concentration (t 1/2) 15.93±9.55 hours and for silicon were C Max 2.99±0.63 μg/mL, t Max 2.44±2.05 hours, and t 1/2 34.56±16.56 hours.","A clinical evaluation to determine the safety, pharmacokinetics, and pharmacodynamics of an inositol-stabilized arginine silicate dietary supplement in healthy adult males. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26504409/),h,34.56,95773,DB03106,Myo-Inositol
,28250348,t1/2,"Cesium-137 (137Cs) (t1/2=30.1 year), a water-soluble radionuclide with a long physical half-life, contaminates aquatic ecosystems and food products.",Complexes of myo-Inositol-Hexakisphosphate (IP6) with Zinc or Lanthanum for the Decorporation of Radiocesium. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28250348/),year,30.1,97115,DB03106,Myo-Inositol
,8167382,half-life,"Tolrestat was administered by gavage (1 x 150 mg/kg, or 5, and 15 mg/kg/day for 15 days to attain steady state as estimated from the 53-h half-life of tolrestat determined in rat nerve); subsequently, at six time intervals, ranging from 4 to 59 days, rats were given access for 4 days to a 20% galactose diet, and killed.",Tolrestat pharmacokinetics in rat peripheral nerve. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8167382/),h,53,101819,DB03106,Myo-Inositol
,31382802,Tmax,Results: The Cmax of MI alone (Tmax = 180min) was 1.29-fold higher than those of MI with DCI (Tmax = 180min) (p < 0.001) and 1.69-fold higher than those of MI with PCQ-SMS (Tmax = 240min) (p < 0.001).,Risk of reduced intestinal absorption of myo-inositol caused by D-chiro-inositol or by glucose transporter inhibitors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31382802/),min,180,105295,DB03106,Myo-Inositol
,31382802,Tmax,Results: The Cmax of MI alone (Tmax = 180min) was 1.29-fold higher than those of MI with DCI (Tmax = 180min) (p < 0.001) and 1.69-fold higher than those of MI with PCQ-SMS (Tmax = 240min) (p < 0.001).,Risk of reduced intestinal absorption of myo-inositol caused by D-chiro-inositol or by glucose transporter inhibitors. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31382802/),min,240,105296,DB03106,Myo-Inositol
,34155211,maximum tolerated dose,"The maximum tolerated dose is 12,390 mg/m2, and ITPP treatment results in 32 treatment-related toxicities (mostly hypercalcemia) that require little or no intervention.",Phase Ib dose-escalation study of the hypoxia-modifier Myo-inositol trispyrophosphate in patients with hepatopancreatobiliary tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34155211/),[mg] / [m2],"12,390",105479,DB03106,Myo-Inositol
,16002804,fractional absorption,Mean fractional absorption of calcium from tortillas prepared from the low-phytate maize (0.50 +/- 0.03) was significantly (P = 0.003) greater than that from tortillas prepared from the control maize (0.35 +/- 0.07).,Absorption of calcium from tortilla meals prepared from low-phytate maize. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16002804/),,0.50,112101,DB03106,Myo-Inositol
,16002804,fractional absorption,Mean fractional absorption of calcium from tortillas prepared from the low-phytate maize (0.50 +/- 0.03) was significantly (P = 0.003) greater than that from tortillas prepared from the control maize (0.35 +/- 0.07).,Absorption of calcium from tortilla meals prepared from low-phytate maize. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16002804/),,0.35,112102,DB03106,Myo-Inositol
less,26594027,oral bioavailability (BA),"The oral bioavailability (BA) of risedronate sodium (RS), an antiresorptive agent, is less than 1% due to its low membrane permeability as well as the formation of non-absorbable complexes with multivalent cations such as calcium ion (Ca(2+)) in the gastrointestinal tract.","Enteric-coated tablet of risedronate sodium in combination with phytic acid, a natural chelating agent, for improved oral bioavailability. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26594027/),%,1,113422,DB03106,Myo-Inositol
,25544113,iron,"The geometric means of iron bioavailability (range±1SD) for iron alone, iron with phytic acid, iron with tannic acid, and iron with citrus pectin were 25.0% (11.9-52.0); 18.9% (9.9-35.8); 16.8% (8.7-32.3); and 21.1% (10.2-43.9), respectively (repeated-measures ANOVA, p<0.02 (Dunnett's post hoc: control vs tannic acid p<0.05).","Effect of phytic acid, tannic acid and pectin on fasting iron bioavailability both in the presence and absence of calcium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544113/),%,25.0,119225,DB03106,Myo-Inositol
,25544113,bioavailability,"The geometric means of iron bioavailability (range±1SD) for iron alone, iron with phytic acid, iron with tannic acid, and iron with citrus pectin were 25.0% (11.9-52.0); 18.9% (9.9-35.8); 16.8% (8.7-32.3); and 21.1% (10.2-43.9), respectively (repeated-measures ANOVA, p<0.02 (Dunnett's post hoc: control vs tannic acid p<0.05).","Effect of phytic acid, tannic acid and pectin on fasting iron bioavailability both in the presence and absence of calcium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544113/),%,25.0,119226,DB03106,Myo-Inositol
,25544113,bioavailability,"The geometric means of iron bioavailability (range±1SD) for iron alone, iron with phytic acid, iron with tannic acid, and iron with citrus pectin were 25.0% (11.9-52.0); 18.9% (9.9-35.8); 16.8% (8.7-32.3); and 21.1% (10.2-43.9), respectively (repeated-measures ANOVA, p<0.02 (Dunnett's post hoc: control vs tannic acid p<0.05).","Effect of phytic acid, tannic acid and pectin on fasting iron bioavailability both in the presence and absence of calcium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544113/),%,18.9,119227,DB03106,Myo-Inositol
,25544113,bioavailability,"The geometric means of iron bioavailability (range±1SD) for iron alone, iron with phytic acid, iron with tannic acid, and iron with citrus pectin were 25.0% (11.9-52.0); 18.9% (9.9-35.8); 16.8% (8.7-32.3); and 21.1% (10.2-43.9), respectively (repeated-measures ANOVA, p<0.02 (Dunnett's post hoc: control vs tannic acid p<0.05).","Effect of phytic acid, tannic acid and pectin on fasting iron bioavailability both in the presence and absence of calcium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544113/),%,16.8,119228,DB03106,Myo-Inositol
,25544113,bioavailability,"The geometric means of iron bioavailability (range±1SD) for iron alone, iron with phytic acid, iron with tannic acid, and iron with citrus pectin were 25.0% (11.9-52.0); 18.9% (9.9-35.8); 16.8% (8.7-32.3); and 21.1% (10.2-43.9), respectively (repeated-measures ANOVA, p<0.02 (Dunnett's post hoc: control vs tannic acid p<0.05).","Effect of phytic acid, tannic acid and pectin on fasting iron bioavailability both in the presence and absence of calcium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544113/),%,21.1,119229,DB03106,Myo-Inositol
,25544113,iron bioavailability,"When 800mg of calcium was added (study B), iron bioavailability was 16.7% (10.1-27.5); 13.2% (7.1-24.6); 14.8% (8.8-25.1); and 12.6% (5.5-28.8), respectively (repeated-measures ANOVA, NS).","Effect of phytic acid, tannic acid and pectin on fasting iron bioavailability both in the presence and absence of calcium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544113/),%,16.7,119230,DB03106,Myo-Inositol
,25544113,iron bioavailability,"When 800mg of calcium was added (study B), iron bioavailability was 16.7% (10.1-27.5); 13.2% (7.1-24.6); 14.8% (8.8-25.1); and 12.6% (5.5-28.8), respectively (repeated-measures ANOVA, NS).","Effect of phytic acid, tannic acid and pectin on fasting iron bioavailability both in the presence and absence of calcium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544113/),%,13.2,119231,DB03106,Myo-Inositol
,25544113,iron bioavailability,"When 800mg of calcium was added (study B), iron bioavailability was 16.7% (10.1-27.5); 13.2% (7.1-24.6); 14.8% (8.8-25.1); and 12.6% (5.5-28.8), respectively (repeated-measures ANOVA, NS).","Effect of phytic acid, tannic acid and pectin on fasting iron bioavailability both in the presence and absence of calcium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544113/),%,14.8,119232,DB03106,Myo-Inositol
,25544113,iron bioavailability,"When 800mg of calcium was added (study B), iron bioavailability was 16.7% (10.1-27.5); 13.2% (7.1-24.6); 14.8% (8.8-25.1); and 12.6% (5.5-28.8), respectively (repeated-measures ANOVA, NS).","Effect of phytic acid, tannic acid and pectin on fasting iron bioavailability both in the presence and absence of calcium. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25544113/),%,12.6,119233,DB03106,Myo-Inositol
,18095642,ED50,"Compound 7d (lorcaserin, APD356) was identified as one of the more potent and selective compounds in vitro (pEC50 values in functional assays measuring [(3)H]phosphoinositol turnover: 5-HT2C = 8.1; 5-HT2A = 6.8; 5-HT2B = 6.1) and was potent in an acute in vivo rat food intake model upon oral administration (ED50 at 6 h = 18 mg/kg).","Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18095642/),mg,18,133564,DB03106,Myo-Inositol
,18095642,t1/2,Lorcaserin was further characterized in a single-dose pharmacokinetic study in rat (t1/2 = 3.7 h; F = 86%) and a 28-day model of weight gain in growing Sprague-Dawley rat (8.5% decrease in weight gain observed at 36 mg/kg b.i.d.).,"Discovery and structure-activity relationship of (1R)-8-chloro-2,3,4,5-tetrahydro-1-methyl-1H-3-benzazepine (Lorcaserin), a selective serotonin 5-HT2C receptor agonist for the treatment of obesity. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18095642/),h,3.7,133565,DB03106,Myo-Inositol
,10427162,peak GH concentration,"At the highest dose (20 micromol/kg), a 35-fold increase in peak GH concentration was observed (49.5+/-17.8 ng/ml, mean+/-s.e.m.).","Pharmacological characterisation of a new oral GH secretagogue, NN703. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10427162/),[ng] / [ml],49.5,136029,DB03106,Myo-Inositol
,10427162,peak GH plasma concentration,After a single i.v. dose of 1 micromol/kg the peak GH plasma concentration was elevated to 38.5+/-19.6 ng/ml (mean+/-s.e.m.) approximately 30 min after dosing and returned to basal level after 360 min.,"Pharmacological characterisation of a new oral GH secretagogue, NN703. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10427162/),[ng] / [ml],38.5,136030,DB03106,Myo-Inositol
,10427162,oral bioavailability,The oral bioavailability was 30%.,"Pharmacological characterisation of a new oral GH secretagogue, NN703. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10427162/),%,30,136031,DB03106,Myo-Inositol
,10427162,plasma half-life,The plasma half-life of NN703 was 4.1+/-0.4 h.,"Pharmacological characterisation of a new oral GH secretagogue, NN703. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10427162/),h,4.1,136032,DB03106,Myo-Inositol
,18207467,flow rate,"Inositol hexanicotinate and the internal standard (mebendazole) were separated isocratically using a mobile phase of acetonitrile/phosphate buffer (35:65, v/v, pH 6.0) at a flow rate of 1.0mL/min and a reverse-phase XTerra MS C(18) column (4.6mmx150mm, 3.5microm).",Determination of inositol hexanicotinate in rat plasma by high performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18207467/),[ml] / [min],1.0,151164,DB03106,Myo-Inositol
,18207467,recovery,"At plasma concentrations of 1.5-100microg/mL, the mean recovery of inositol hexanicotinate was 99.6%.",Determination of inositol hexanicotinate in rat plasma by high performance liquid chromatography with UV detection. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18207467/),%,99.6,151165,DB03106,Myo-Inositol
>,23121445,oral bioavailability,"In vivo, AQX-1125 exhibited >80% oral bioavailability and >5 h terminal half-life.","Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23121445/),%,80,152002,DB03106,Myo-Inositol
>,23121445,terminal half-life,"In vivo, AQX-1125 exhibited >80% oral bioavailability and >5 h terminal half-life.","Characterization of AQX-1125, a small-molecule SHIP1 activator: Part 1. Effects on inflammatory cell activation and chemotaxis in vitro and pharmacokinetic characterization in vivo. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23121445/),h,5,152003,DB03106,Myo-Inositol
,19628629,K(i),APD791 displayed high-affinity binding to membranes (K(i) = 4.9 nM) and functional inverse agonism of inositol phosphate accumulation (IC(50) = 5.2 nM) in human embryonic kidney cells stably expressing the human 5-HT(2A) receptor.,"APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology. ",Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628629/),nM,4.9,154834,DB03106,Myo-Inositol
,19628629,IC(50),APD791 displayed high-affinity binding to membranes (K(i) = 4.9 nM) and functional inverse agonism of inositol phosphate accumulation (IC(50) = 5.2 nM) in human embryonic kidney cells stably expressing the human 5-HT(2A) receptor.,"APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628629/),nM,5.2,154835,DB03106,Myo-Inositol
,19628629,IC(50),"APD791 inhibited 5-HT-mediated amplification of ADP-stimulated human and dog platelet aggregation (IC(50) = 8.7 and 23.1 nM, respectively).","APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628629/),nM,8.7,154836,DB03106,Myo-Inositol
,19628629,IC(50),"APD791 inhibited 5-HT-mediated amplification of ADP-stimulated human and dog platelet aggregation (IC(50) = 8.7 and 23.1 nM, respectively).","APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628629/),nM,23.1,154837,DB03106,Myo-Inositol
,19628629,IC(50),Similar potency was observed for inhibition of 5-HT-stimulated DNA synthesis in rabbit aortic smooth muscle cells (IC(50) = 13 nM) and 5-HT-mediated vasoconstriction in rabbit aortic rings.,"APD791, 3-methoxy-n-(3-(1-methyl-1h-pyrazol-5-yl)-4-(2-morpholinoethoxy)phenyl)benzamide, a novel 5-hydroxytryptamine 2A receptor antagonist: pharmacological profile, pharmacokinetics, platelet activity and vascular biology. ",IC50-Q10,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19628629/),nM,13,154838,DB03106,Myo-Inositol
,8249876,recovery,"Mean polyethylene glycol (PEG) recovery, a nonabsorbable fecal marker, was 95 +/- 2% (mean +/- SE).",Measurement of zinc bioavailability from beef and a ready-to-eat high-fiber breakfast cereal in humans: application of a whole-gut lavage technique. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8249876/),%,95,178579,DB03106,Myo-Inositol
,8249876,True absorption,True absorption of zinc was 11.0 +/- 5.4 mumol (716.3 +/- 355.9 micrograms) for breakfast cereal and 34.8 +/- 3.5 mumol (2274.1 +/- 230.2 micrograms) for beef.,Measurement of zinc bioavailability from beef and a ready-to-eat high-fiber breakfast cereal in humans: application of a whole-gut lavage technique. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8249876/),μM,11.0,178580,DB03106,Myo-Inositol
,8249876,True absorption,True absorption of zinc was 11.0 +/- 5.4 mumol (716.3 +/- 355.9 micrograms) for breakfast cereal and 34.8 +/- 3.5 mumol (2274.1 +/- 230.2 micrograms) for beef.,Measurement of zinc bioavailability from beef and a ready-to-eat high-fiber breakfast cereal in humans: application of a whole-gut lavage technique. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8249876/),μg,716.3,178581,DB03106,Myo-Inositol
,8249876,True absorption,True absorption of zinc was 11.0 +/- 5.4 mumol (716.3 +/- 355.9 micrograms) for breakfast cereal and 34.8 +/- 3.5 mumol (2274.1 +/- 230.2 micrograms) for beef.,Measurement of zinc bioavailability from beef and a ready-to-eat high-fiber breakfast cereal in humans: application of a whole-gut lavage technique. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8249876/),μM,34.8,178582,DB03106,Myo-Inositol
,8249876,True absorption,True absorption of zinc was 11.0 +/- 5.4 mumol (716.3 +/- 355.9 micrograms) for breakfast cereal and 34.8 +/- 3.5 mumol (2274.1 +/- 230.2 micrograms) for beef.,Measurement of zinc bioavailability from beef and a ready-to-eat high-fiber breakfast cereal in humans: application of a whole-gut lavage technique. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8249876/),μg,2274.1,178583,DB03106,Myo-Inositol
,8249876,Fractional zinc absorption,"Fractional zinc absorption was significantly lower for breakfast cereal compared with beef, 14.7 +/- 6.7% vs 55.1 +/- 4.6%, respectively.",Measurement of zinc bioavailability from beef and a ready-to-eat high-fiber breakfast cereal in humans: application of a whole-gut lavage technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8249876/),%,14.7,178584,DB03106,Myo-Inositol
,8249876,Fractional zinc absorption,"Fractional zinc absorption was significantly lower for breakfast cereal compared with beef, 14.7 +/- 6.7% vs 55.1 +/- 4.6%, respectively.",Measurement of zinc bioavailability from beef and a ready-to-eat high-fiber breakfast cereal in humans: application of a whole-gut lavage technique. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8249876/),%,55.1,178585,DB03106,Myo-Inositol
,7994371,Circulation half-lives,"Circulation half-lives following 50% isovolemic exchange-transfusion in rats were also similar, about 15-20 hours for either formation.","Efficacy, physical properties and pharmacokinetics of sterically-stabilized liposome-encapsulated hemoglobin. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7994371/),h,15-20,198347,DB03106,Myo-Inositol
,33196464,AUC,"RESULTSIn healthy women, the amplitude of luteinizing hormone (LH) rise was similar to that after KP54, but peaked later (21.4 vs. 4.7 hours; P = 0.0002), with correspondingly increased AUC of LH exposure (169.0 vs. 38.5 IU∙h/L; P = 0.0058).",Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196464/),[iu∙h] / [l],169.0,212089,DB03106,Myo-Inositol
,33196464,AUC,"RESULTSIn healthy women, the amplitude of luteinizing hormone (LH) rise was similar to that after KP54, but peaked later (21.4 vs. 4.7 hours; P = 0.0002), with correspondingly increased AUC of LH exposure (169.0 vs. 38.5 IU∙h/L; P = 0.0058).",Kisspeptin receptor agonist has therapeutic potential for female reproductive disorders. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33196464/),[iu∙h] / [l],38.5,212090,DB03106,Myo-Inositol
,24067395,central volume of distribution,"The central volume of distribution was 0.5115 l/kg, the clearance was 0.0679 l/kg/h, endogenous production was 2.67 mg/kg/h, and the half-life was 5.22 h when modeled without the covariates.",Pharmacokinetics and safety of a single intravenous dose of myo-inositol in preterm infants of 23-29 wk. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24067395/),[l] / [kg],0.5115,220176,DB03106,Myo-Inositol
,24067395,clearance,"The central volume of distribution was 0.5115 l/kg, the clearance was 0.0679 l/kg/h, endogenous production was 2.67 mg/kg/h, and the half-life was 5.22 h when modeled without the covariates.",Pharmacokinetics and safety of a single intravenous dose of myo-inositol in preterm infants of 23-29 wk. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24067395/),[l] / [h·kg],0.0679,220177,DB03106,Myo-Inositol
,24067395,half-life,"The central volume of distribution was 0.5115 l/kg, the clearance was 0.0679 l/kg/h, endogenous production was 2.67 mg/kg/h, and the half-life was 5.22 h when modeled without the covariates.",Pharmacokinetics and safety of a single intravenous dose of myo-inositol in preterm infants of 23-29 wk. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24067395/),h,5.22,220178,DB03106,Myo-Inositol
,3108736,uptake,Depending on the colloid type liver uptake was between 54 and 75% of the total administered dose (TAD) and spleen uptake was 3.5 to 21% TAD.,Absolute quantification of pharmacokinetic distribution of RES colloids in individuals with normal liver function. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3108736/),%,3.5 to 21,220247,DB03106,Myo-Inositol
,2013113,transfer rate,"For liposomal MTO a transfer rate of 48% was determined, whereas 75.8% of free MTO was bound to the plasma proteins.","Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013113/),%,48,241475,DB03106,Myo-Inositol
,2013113,terminal elimination halflives,The terminal elimination halflives in the liver were 77 h for liposomal MTO and 14.4 h for free MTO.,"Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013113/),h,77,241476,DB03106,Myo-Inositol
,2013113,terminal elimination halflives,The terminal elimination halflives in the liver were 77 h for liposomal MTO and 14.4 h for free MTO.,"Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013113/),h,14.4,241477,DB03106,Myo-Inositol
,2013113,LD25,The LD25 of PA-MTO liposomes in mice was 19.6 mg/kg and that of free MTO was 7.7 mg/kg.,"Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013113/),[mg] / [kg],19.6,241478,DB03106,Myo-Inositol
,2013113,LD25,The LD25 of PA-MTO liposomes in mice was 19.6 mg/kg and that of free MTO was 7.7 mg/kg.,"Evaluation of incorporation characteristics of mitoxantrone into unilamellar liposomes and analysis of their pharmacokinetic properties, acute toxicity, and antitumor efficacy. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2013113/),[mg] / [kg],7.7,241479,DB03106,Myo-Inositol
,19346319,half-life,"[(3)H]INO-4995 was rapidly taken up by epithelial cultures and converted to the active drug, which had a half-life of 40 hours.",INO-4995 therapeutic efficacy is enhanced with repeat dosing in cystic fibrosis knockout mice and human epithelia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19346319/),h,40,241899,DB03106,Myo-Inositol
,27074126,volume of distribution,"Analyses showed a mean volume of distribution 0.657 l/kg, clearance 0.058 l/kg/h, and half-life 7.90 h.",Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27074126/),[l] / [kg],0.657,244017,DB03106,Myo-Inositol
,27074126,clearance,"Analyses showed a mean volume of distribution 0.657 l/kg, clearance 0.058 l/kg/h, and half-life 7.90 h.",Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27074126/),[l] / [h·kg],0.058,244018,DB03106,Myo-Inositol
,27074126,half-life,"Analyses showed a mean volume of distribution 0.657 l/kg, clearance 0.058 l/kg/h, and half-life 7.90 h.",Safety and pharmacokinetics of multiple dose myo-inositol in preterm infants. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27074126/),h,7.90,244019,DB03106,Myo-Inositol
,33388525,MRM,"The MRM transitions for D-pinitol was m/z 179.125 → 105.049, and for IS was m/z 195.085 → 109.031.",An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),,179.125,244845,DB03106,Myo-Inositol
,33388525,MRM,"The MRM transitions for D-pinitol was m/z 179.125 → 105.049, and for IS was m/z 195.085 → 109.031.",An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),,105.049,244846,DB03106,Myo-Inositol
,33388525,MRM,"The MRM transitions for D-pinitol was m/z 179.125 → 105.049, and for IS was m/z 195.085 → 109.031.",An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),,195.085,244847,DB03106,Myo-Inositol
,33388525,m/z,"The MRM transitions for D-pinitol was m/z 179.125 → 105.049, and for IS was m/z 195.085 → 109.031.",An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),,179.125,244848,DB03106,Myo-Inositol
,33388525,m/z,"The MRM transitions for D-pinitol was m/z 179.125 → 105.049, and for IS was m/z 195.085 → 109.031.",An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),,105.049,244849,DB03106,Myo-Inositol
,33388525,m/,"The MRM transitions for D-pinitol was m/z 179.125 → 105.049, and for IS was m/z 195.085 → 109.031.",An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),,195.085,244850,DB03106,Myo-Inositol
,33388525,m/,"The MRM transitions for D-pinitol was m/z 179.125 → 105.049, and for IS was m/z 195.085 → 109.031.",An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),,109.031,244851,DB03106,Myo-Inositol
,33388525,linearity,The method linearity ranges was 5-200 ng/mL.,An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),[ng] / [ml],5-200,244852,DB03106,Myo-Inositol
,33388525,maximum plasma concentration (Cmax),"After intragastric (50 mg/kg) administration of D-pinitol to the rats, the maximum plasma concentration (Cmax) was 77.8 ± 19.5 ng/mL.",An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),[ng] / [ml],77.8,244853,DB03106,Myo-Inositol
,33388525,time to reach the maximum plasma concentration (Tmax),The time to reach the maximum plasma concentration (Tmax) was 2.2 ± 0.98 h.,An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),h,2.2,244854,DB03106,Myo-Inositol
,33388525,Apparent distribution volume (Vz),Apparent distribution volume (Vz) was 1557.5 ± 1329.1 L/kg and the plasma centration time curve (AUC0-t) was 1265.5 ± 479.3 µg/L*h.,An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),[l] / [kg],1557.5,244855,DB03106,Myo-Inositol
,33388525,plasma centration time curve (AUC0-t),Apparent distribution volume (Vz) was 1557.5 ± 1329.1 L/kg and the plasma centration time curve (AUC0-t) was 1265.5 ± 479.3 µg/L*h.,An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),[μg] / [h·l],1265.5,244856,DB03106,Myo-Inositol
,33388525,Vz,"After intravenous (5.0 mg/kg) administration, Vz was 325.2 ± 107.8 L/kg and AUC(0-t) was 693.0 ± 89.9 µg/L*h.",An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),[l] / [kg],325.2,244857,DB03106,Myo-Inositol
,33388525,AUC(0-t),"After intravenous (5.0 mg/kg) administration, Vz was 325.2 ± 107.8 L/kg and AUC(0-t) was 693.0 ± 89.9 µg/L*h.",An UPLC-MS/MS method for quantification of D-pinitol in rat plasma and its application to a pharmacokinetic and bioavailability study. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33388525/),[μg] / [h·l],693.0,244858,DB03106,Myo-Inositol
,930544,Absorption,Absorption of clofibric acid was found to be identical with that obtained with ethyl-alpha-p-chlorphenoxyisobutyrate (Clofibrate) reaching almost 100%.,[Pharmacokinetics of a combination of magnesium-chlorophenoxy-isobutyrate and meso-inositol hexanicotinate]. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/930544/),%,100,261945,DB03106,Myo-Inositol
,930544,Urinary excretion,Urinary excretion of clofibric acid for both the combination drug and Clofibrate was 90% in 48 hours.,[Pharmacokinetics of a combination of magnesium-chlorophenoxy-isobutyrate and meso-inositol hexanicotinate]. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/930544/),%,90,261946,DB03106,Myo-Inositol
,24462958,logP,"The lipophilicity of the three flavonoids was slightly decreased, but their hydrophilicity was increased after the addition of IP6 in the water phase as the logP values of isorhamnetin, kaempferol, and quercetin decreased from 2.38±0.12 to 1.64±0.02, from 2.57±0.20 to 2.01±0.04, and from 2.39±0.12 to 1.15±0.01, respectively.","Phytic acid enhances the oral absorption of isorhamnetin, quercetin, and kaempferol in total flavones of Hippophae rhamnoides L. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24462958/),,2.38,265481,DB03106,Myo-Inositol
,24462958,logP,"The lipophilicity of the three flavonoids was slightly decreased, but their hydrophilicity was increased after the addition of IP6 in the water phase as the logP values of isorhamnetin, kaempferol, and quercetin decreased from 2.38±0.12 to 1.64±0.02, from 2.57±0.20 to 2.01±0.04, and from 2.39±0.12 to 1.15±0.01, respectively.","Phytic acid enhances the oral absorption of isorhamnetin, quercetin, and kaempferol in total flavones of Hippophae rhamnoides L. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24462958/),,1.64,265482,DB03106,Myo-Inositol
,24462958,logP,"The lipophilicity of the three flavonoids was slightly decreased, but their hydrophilicity was increased after the addition of IP6 in the water phase as the logP values of isorhamnetin, kaempferol, and quercetin decreased from 2.38±0.12 to 1.64±0.02, from 2.57±0.20 to 2.01±0.04, and from 2.39±0.12 to 1.15±0.01, respectively.","Phytic acid enhances the oral absorption of isorhamnetin, quercetin, and kaempferol in total flavones of Hippophae rhamnoides L. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24462958/),,2.57,265483,DB03106,Myo-Inositol
,24462958,logP,"The lipophilicity of the three flavonoids was slightly decreased, but their hydrophilicity was increased after the addition of IP6 in the water phase as the logP values of isorhamnetin, kaempferol, and quercetin decreased from 2.38±0.12 to 1.64±0.02, from 2.57±0.20 to 2.01±0.04, and from 2.39±0.12 to 1.15±0.01, respectively.","Phytic acid enhances the oral absorption of isorhamnetin, quercetin, and kaempferol in total flavones of Hippophae rhamnoides L. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24462958/),,2.01,265484,DB03106,Myo-Inositol
,24462958,logP,"The lipophilicity of the three flavonoids was slightly decreased, but their hydrophilicity was increased after the addition of IP6 in the water phase as the logP values of isorhamnetin, kaempferol, and quercetin decreased from 2.38±0.12 to 1.64±0.02, from 2.57±0.20 to 2.01±0.04, and from 2.39±0.12 to 1.15±0.01, respectively.","Phytic acid enhances the oral absorption of isorhamnetin, quercetin, and kaempferol in total flavones of Hippophae rhamnoides L. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24462958/),,2.39,265485,DB03106,Myo-Inositol
,24462958,logP,"The lipophilicity of the three flavonoids was slightly decreased, but their hydrophilicity was increased after the addition of IP6 in the water phase as the logP values of isorhamnetin, kaempferol, and quercetin decreased from 2.38±0.12 to 1.64±0.02, from 2.57±0.20 to 2.01±0.04, and from 2.39±0.12 to 1.15±0.01, respectively.","Phytic acid enhances the oral absorption of isorhamnetin, quercetin, and kaempferol in total flavones of Hippophae rhamnoides L. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24462958/),,1.15,265486,DB03106,Myo-Inositol
,24462958,absorption enhancement ratios,"The absorption enhancement ratios were 3.21 for isorhamnetin, 2.98 for kaempferol, and 1.64 for quercetin with co-administration of IP6 (200 mg/kg) in rats.","Phytic acid enhances the oral absorption of isorhamnetin, quercetin, and kaempferol in total flavones of Hippophae rhamnoides L. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24462958/),,3.21,265487,DB03106,Myo-Inositol
,24462958,absorption enhancement ratios,"The absorption enhancement ratios were 3.21 for isorhamnetin, 2.98 for kaempferol, and 1.64 for quercetin with co-administration of IP6 (200 mg/kg) in rats.","Phytic acid enhances the oral absorption of isorhamnetin, quercetin, and kaempferol in total flavones of Hippophae rhamnoides L. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24462958/),,2.98,265488,DB03106,Myo-Inositol
,24462958,absorption enhancement ratios,"The absorption enhancement ratios were 3.21 for isorhamnetin, 2.98 for kaempferol, and 1.64 for quercetin with co-administration of IP6 (200 mg/kg) in rats.","Phytic acid enhances the oral absorption of isorhamnetin, quercetin, and kaempferol in total flavones of Hippophae rhamnoides L. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24462958/),,1.64,265489,DB03106,Myo-Inositol
